Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Allowed: BRAF mutation

mutations in BRAF

Allowed: FGFR1 mutation

mutations in FGFR

Allowed: PTPN11 mutation

mutations in PTPN11

Allowed: NF1 mutation

somatic NF-1

Allowed: NF1 syndrome-associated gliomas

NF-1 syndrome-associated gliomas

Allowed: CIC mutation

CIC mutated

Allowed: MAPK1 activation

mutation or activation of the RAS/RAF/MEK/ERK pathway

Must have received: radiation therapy — low grade glioma (grade 1, 2), oligodendroglioma (grade 2, 3), high grade glioma (grades 3 and 4 excluding oligodendroglioma)

Low grade gliomas patients (grade 1, 2) and oligodendroglioma (grade 2, 3) must have had prior radiation OR chemotherapy for the treatment of glioma. High grade glioma patients (grades 3 and 4 excluding oligodendroglioma) must have had prior radiation.

Must have received: chemotherapy — low grade glioma (grade 1, 2), oligodendroglioma (grade 2, 3)

Low grade gliomas patients (grade 1, 2) and oligodendroglioma (grade 2, 3) must have had prior radiation OR chemotherapy for the treatment of glioma.

Cannot have received: VEGF inhibitor (bevacizumab)

Exception: treatment with bevacizumab less than 3 months prior to enrollment

Treatment with bevacizumab less than 3 months prior to enrollment.

Cannot have received: chemotherapy

Exception: prior chemotherapy or targeted small molecule therapy within 3 weeks prior to study Day 1

Patient has had prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to study Day 1

Cannot have received: targeted small molecule therapy

Exception: within 3 weeks prior to study Day 1

Patient has had prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to study Day 1